{
    "clinical_study": {
        "@rank": "75570", 
        "arm_group": [
            {
                "arm_group_label": "naloxone intranasal", 
                "arm_group_type": "Experimental", 
                "description": "2.0 mg by the nasal route"
            }, 
            {
                "arm_group_label": "naloxone intravenous", 
                "arm_group_type": "Active Comparator", 
                "description": "1.0 mg intravenous"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall is aim of this pilot study is to give a preliminary estimation of key parameters\n      of the pharmacokinetics of a proper formulation of intranasal naloxone. These data will be\n      used to design a well justified protocol for the final estimation of these parameters:\n\n        -  Preliminary estimation of bioavailability of this intranasal naloxone in human, healthy\n           volunteers\n\n        -  Preliminary estimation of the maximum serum concentration (Cmax) of this formulation\n\n        -  Preliminary estimation of  the time to maximum serum concentration (Tmax) of this\n           formulation\n\n        -  Safety of the formulation"
        }, 
        "brief_title": "A Pilot Study of the Bioavailability of Nasal Naloxone", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug Overdose", 
        "condition_browse": {
            "mesh_term": "Overdose"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy (adequate organ function is determined by electrocardiogram (ECG), liver and\n             kidney clinical chemistry, and a standard clinical examination/interview. For safety\n             reasons we may ask for urine sample for analysis of opioids)\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  history of liver disease\n\n          -  taking any medications including herbal medicines the last week history of drug abuse\n\n          -  any local nasal disease or nasal surgery or recent cold for the last week\n\n          -  any history of drug allergies"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939444", 
            "org_study_id": "OPI-12-001", 
            "secondary_id": "2012-004989-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "naloxone intranasal", 
                "description": "If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally", 
                "intervention_name": "naloxone intranasal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "naloxone intravenous", 
                "description": "The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position", 
                "intervention_name": "naloxone intravenous", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naloxone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Antidotes", 
            "naloxone", 
            "administration, intravenous", 
            "administration, intranasal", 
            "pharmacology"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Trondheim", 
                    "country": "Norway"
                }, 
                "name": "Department of circulation and medical imaging, NTNU"
            }
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of the Bioavailability of Nasal Naloxone", 
        "overall_official": {
            "affiliation": "Norwegian University of Science and Technology", 
            "last_name": "\u00d8yvind Ellingsen, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Norway: Regional Ethics Commitee", 
                "Norway: Norwegian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measured as ratio of area under the time concentration curve for nasal over intravenous naloxone x 100. Plasma concentration data will be analyzed by non-compartmental techniques.", 
            "measure": "preliminary bioavailability of nasal naloxone", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "time to maximum concentrations", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "maximum concentration", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Norwegian University of Science and Technology", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "St. Olavs Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Iceland", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Norwegian University of Science and Technology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}